Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma.
It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 205 |
| CEO | Andrew Robbins |
Contact Details
Address: 275 Wyman Street, 3rd Floor Waltham, Massachusetts 02451 United States | |
| Phone | 617 945 5576 |
| Website | cogentbio.com |
Stock Details
| Ticker Symbol | COGT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001622229 |
| CUSIP Number | 19240Q201 |
| ISIN Number | US19240Q2012 |
| Employer ID | 46-5308248 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew R. Robbins M.B.A. | President, Chief Executive Officer and Director |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| John L. Green C.A., CPA | Chief Financial Officer and Principal Accounting Officer |
| Brad Barnett | Chief Technology Officer |
| Christi Waarich | Senior Director of Investor Relations |
| Evan D. Kearns J.D. | Chief Legal Officer and Corporate Secretary |
| Erin Schellhammer | Chief People Officer |
| Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs and Chief Patient Officer |
| Brad Fell | Senior Vice President of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 25, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Dec 9, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |